LIU Jian, LI Xue-rui. Chemotherapy with Bevacizumab for First-Line Treatment of HER2 Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 150-152. DOI: 10.3969/j.issn.1671-5144.2012.03.016
|
Citation:
|
LIU Jian, LI Xue-rui. Chemotherapy with Bevacizumab for First-Line Treatment of HER2 Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 150-152. DOI: 10.3969/j.issn.1671-5144.2012.03.016
|
LIU Jian, LI Xue-rui. Chemotherapy with Bevacizumab for First-Line Treatment of HER2 Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 150-152. DOI: 10.3969/j.issn.1671-5144.2012.03.016
|
Citation:
|
LIU Jian, LI Xue-rui. Chemotherapy with Bevacizumab for First-Line Treatment of HER2 Negative Metastatic Breast Cancer[J]. Journal of Evidence-Based Medicine, 2012, 12(3): 150-152. DOI: 10.3969/j.issn.1671-5144.2012.03.016
|
DownLoad: